Multiple sclerosis is a common, complex neurological disease, where almost 20% of risk heritability can 5 be attributed to common genetic variants, including >230 identified by genome-wide association studies 6 . Multiple strands of evidence suggest that the majority of the remaining 7 heritability is also due to the additive effects of individual variants, rather than epistatic interactions 8 between these variants, or mutations exclusive to individual families. Here, we show in 68,379 cases and 9 controls that as much as 5% of this heritability is explained by low-frequency variation in gene coding 10 sequence. We identify four novel genes driving MS risk independently of common variant signals, which 11 highlight a key role for regulatory T cell homeostasis and regulation, IFNg biology and NFκB signaling in 12 MS pathogenesis. As low-frequency variants do not show substantial linkage disequilibrium with other 13
affected members (Sawcer et al., 2005) . These results indicate that neither epistasis between known risk preclude a role for variants present in the population at low frequencies, which cannot be imputed but production and, eventually, apoptosis (Sadler and Williams, 2008) . NFκB-mediated signaling is a core feature of MS pathogenesis, which we have shown to be altered by at least one MS-associated variant
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Table 1 -coding variants associated to multiple sclerosis risk. We analyzed 144,209 low-frequency are relative to hg19. The two variants in PRKRA are in linkage disequilibrium (R 2 = 1, D` = 1 in HapMap Figure 1 -rare coding variants are associated to multiple sclerosis risk in a multi-cohort study.
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Figure 2 -rare variants explain a substantial portion of multiple sclerosis heritability. We 166 estimated the MS risk heritability explained by common variants (MAF > 5%) and low-frequency 167 nonsynonymous coding variation (MAF < 5%) in each of thirteen cohorts genotyped on the exome chip, 168 using GCTA (top panel). By meta-analyzing these estimates across cohorts, we found that low-frequency 169 variants explain 11.34% of heritability on the observed scale, which corresponds to 4.1% on the liability 170 scale (right top). After dividing the low-frequency variants into intermediate (5% > MAF > 1 %) and rare 171 (MAF <1%; bottom panel), we found that the latter alone explain 9.0% heritability on the observed scale (3.2% on the liability scale; bottom right). Meta-analysis confidence intervals are small and visually sample size, with the percentage of the overall sample size shown in each subplot title. We could not 
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Methods

Genotyping, quality control and stratum assignment
We assembled a total of 76,140 samples (36,219 cases, 38,629 controls and 1,292 samples with missing phenotype information) from across the International MS Genetics Consortium (IMSGC ; Table S1 ). We genotyped these either on the Illumina HumanExome Beadchip (exome chip) or on a previously described custom array including the exome chip content, both manufactured by Illumina Inc. We called genotypes both with Illumina's default algorithm, gencall, and zCall, specifically developed to call lowfrequency variants where all three groups of genotypes may not be observed ). An overview of our quality control process is shown in Figure S1 ; we used plink (Purcell et al., 2007) for all analyses unless otherwise noted. Briefly, we first excluded samples with low genotyping rate, extreme heterozygosity rate, inconsistent genotypic and recorded sex; we also removed closely related samples, keeping the relative with least missing data. Next, we removed population outliers by calculating genotype principal components using 16,066 common variants in linkage disequilibrium (r 2 < 0.1) across the exome. We used EIGENSOFT 6 (Price et al., 2006) and FlashPCA (Abraham and Inouye, 2014) for cohorts with more than 10.000 individuals. We next removed variants with >3% gencall missing data rate for variants with minor allele frequency MAF >5%, or >1% zCall missing data rate for variants with MAF < 5%. We also removed variants out of Hardy-Weinberg equilibrium (p < 10 -5 ). Next, we removed samples with high similarity in missing genotypes ("identity by missingness") indicative of production artefact, and samples with missing phenotype information. Finally, we again removed any remaining population outliers using projection principal component analysis. We calculated 30 principal components for 1,092 individuals in 1,000 Genomes reference populations, again using the 16,066 common variants in linkage disequilibrium (r 2 < 0.1) across the exome. We then projected the IMSGC samples into this space and excluded individuals more than six standard deviations from loading means as previously described (Price et al., 2006) . We performed the projection and outlier detection and removal steps a total ten times to gradually remove more subtle population outliers. We compiled cases and controls into strata for analysis as shown in Table S2 . In total, we removed 17,951/76,140 (24%) samples either due to low data quality or as population outliers, leaving a final dataset of 27,891 cases and 30,298 controls in 13 strata ( Figure S1 and Tables S1 and S2). Separately, we included summary statistics from 4,476 MS cases and 5,714 controls from Germany, genotyped on the exome chip as previously described (Dankowski et al., 2015) , giving us a total of 32,367 MS cases and 36,012 controls for analysis.
Exome chip coverage of ExAC variants
To assess how thoroughly the exome chip assesses low-frequency coding variation genome-wide, we compared it to the list of variants reported by the Exome Aggregation Consortium, ExAC , in their data release version 1. We filtered their summary table of all ExAC variants (available at ftp://ftp.broadinstitute.org/pub/ExAC_release/release1/manuscript_data/ExAC.r1.sites.vep.table.gz and last accessed 15 November 2017) for nonsynonymous coding variants passing their quality control, with at least one minor allele observed in non-Finnish European samples. We identified which of these variants are represented on the exome chip by comparing genomic coordinates ( Figure S2) .
Univariate association analysis
We used mixed linear models for association analysis, as implemented in GCTA (Yang et al., 2011) . In each of our 13 genotype-level strata, we calculated genetic relatedness matrices from 16,066 common, noncoding variants (overall MAF > 0.05) in linkage equilibrium (all pairwise r 2 < 0.1) present on the exome chip, and with these calculated univariate association statistics for each autosomal variant present on the exome chip. To further control for population stratification, we also calculated genotypic principal components with the 16,066 common variants, and included these as covariates to the association analysis. We also included genotypic sex and chip type as covariates. We combined statistics across strata using inverse-variance-weighted metaanalysis, also as implemented in GCTA (Yang et al., 2011) . As the bulk of exome chip variants are not common and do not show appreciable linkage disequilibrium, we controlled for multiple tests with a Bonferroni correction for the number of low-frequency variants, to give a genome-wide significance threshold of p < 3.58 x 10e -7 (0.05/139,764 variants with a combined MAF < 0.05 in controls and a heterogeneity index I 2 < 50 in our metaanalysis).
Heritability estimation
We used GCTA to calculate the heritability attributable to groups of variants in each of our 13 genotype-level strata (Yang et al., 2011) . In each stratum, we ran two sets of models: a two-component model, estimating the heritability attributable to common and low-frequency (MAF £ 0.05) variants; and a three component model with rare (MAF £ 0.01), intermediate (0.01 < MAF £ 0.05), and common variants. In all strata, common variants are the set of 16,066 independent variants (overall MAF > 0.05) used for population stratification calculations in the univariate analysis above. We computed genetic relatedness matrices for each component of each model, then calculated narrow-sense heritability (h 2 ) with 100 iterations of constrained restricted maximum likelihood (REML) fitting, assuming a disease prevalence of 0.001. We also included the principal components of population structure computed for the univariate analysis as covariates. As anticipated, several of the smaller cohorts presented fitting issues: no models converged for FIN; both three-component and two-component fits for UCSF2, and the three-component model for GRE would not converge under constraint and so were run without constraints; and the three-component model for BEL converged on two exactly equally likely solutions after 10,000 iterations. For the latter, we chose the most conservative estimates of variance explained. We combined these estimates with inverse variance-weighted meta-analysis.
Figure S2 -the exome chip captures a large fraction of ExAC (release version 1) low-frequency misssense variants.
The exome chip captures the majority of variants present in ExAC Figure S3 -effect size correlates with minor allele frequency. We conducted a meta-analysis of 144,209 low-frequency coding variants across all autosomal exons, concentrating on non-synonymous variants which are more likely to have a phenotypic effect. We analyzed a total of 32,367 MS cases and 36,012 controls in thirteen strata. Here, we show that effect size (b or log odds ratio, y axis) correlates to allele frequency (number of minor alleles present in control samples, x axis). Because many low-frequency variants are not present in all cohorts, we stratify these data by number of cohorts in which a variant is polymorphic (subplots). Rarer variants have larger estimated effect sizes, and are present in fewer cohorts. Figure S4 -forest plots for genome-wide significant low-frequency variants. Seven variants in six genes are significant in our analysis (p < 3.5 x 10 -7 , Bonferroni correction for the total number of variants genotyped). Two of these (TYK2 p.Pro1104Ala and GALC p.Asp84Asp), are in linkage disequilibrium with known GWAS hits. Studies are ordered by increasing sample size. S1 -genotype-level samples included in our study. 58,189/76,140 (76.5%) of our samples passed quality control and could be assigned to one of thirteen strata. 9,473/17,951 (52.8%) of failed samples did not pass a heterogeneity versus missing data rate filter, suggesting either poor data quality or population stratification (detailed in Figure S1 ). We used two versions of Illumina's HumanCore Exome array: the standard product (version 1.0; designated Exome_v1.x in the chip type column) and a customized version including ~100,000 additional variants we specified (designated MS_chip), described elsewhere . Belgian control samples were genotyped at the Center for Inherited Disease Research (CIDR, Baltimore, MD, USA) on the Illumina 5M array (Illumina, San Diego, CA, USA) as part of the Stroke Genetics Network (SiGN). Table S2 -final stratum composition. We assigned 58,189 samples passing quality control to one of thirteen strata based on demography as described in the methods; data for 10,190 samples from Germany were received as post-QC summary statistics and are not included in Table S1 . This gave us a total of 68,379 samples in our analysis. We had very few Australian control samples and so merged them with samples from the UK.
